FDA Approves First Drug for Myelofibrosis With Thrombocytopenia
Pacritinib is indicated specifically for patients with myelofibrosis and very low platelet counts, which develop in about one third of patients.
FDA Approvals
source https://www.medscape.com/viewarticle/969389?src=rss
FDA Approvals
source https://www.medscape.com/viewarticle/969389?src=rss
Comments
Post a Comment